[Hengrui Medicine: Outeconazole Capsules were approved for registration and marketing by the State Food and Drug Administration] On September 3, Hengrui Medicine (600276.SH) announced that the company's subsidiary Chengdu Shengdi Medicine received a notice from the State Food and Drug Administration, approving the registration and marketing of domestically produced drugs for Outeconazole Capsules. This drug is used to treat severe vulvovaginal candidiasis. It is a drug that has been marketed and produced overseas and has been transferred to domestic production. The total global sales of similar products of oteconazole in 2025 will be approximately US$2.23 billion, and the cumulative R&D investment in related projects will be approximately RMB 219 million.